Project Grant R41HL176225
Award Date
9/19/24
Completion Date
9/18/25
Dollars Obligated
$276K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Austin, TX 78731, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $790,738 project grant to Circulatech LLC to develop and test the "ThoraFlush" - a proactive, dual-irrigation cardiac chest tube designed to maintain postoperative drainage patency. The project aims to: 1) optimize the efficacy of the ThoraFlush in a mediastinum blood coagulation model, and 2) demonstrate the device's superior drainage volume performance in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the continued clinical development of a novel pleural and tracheal sealant. The $381,000 award to the University of Vermont will fund research to: 1) define optimal manufacturing, sterilization, and storage conditions for the sealant patch; 2) further evaluate the long-term safety and efficacy of the sealant in animal models...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $229,971 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of North Carolina at Chapel Hill (UNC-CH) to develop and test novel hydrogel patches that can prevent air leaks after lung surgery. The goal is to eliminate the need for chest tubes following lung resection procedures, which would reduce complications, costs, and improve patient quality of life. The project involves optimizing the hydrogel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
The federal Project Grant award R01HL176666, totaling $767,077.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award aims to validate and extend a platform technology for the delivery of protein-based drugs, with a specific focus on thrombolytic enzymes and vitamin B12. The research seeks to develop a biocompatible drug delivery system that leverages the circulatory system as a natural drug depot and utilizes...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,488,899 in funding to Young Therapeutics LLC, a pharmaceutical research and development company based in Philadelphia, Pennsylvania. The award supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, that target specific protein kinases to preserve myocardial tissue and function...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $604,750 to Scientific Horizons Consulting LLC to develop a novel inhalation device prototype for the pulmonary delivery of anti-inflammatory agents to the distal airways of patients with chronic obstructive pulmonary disease (COPD). The key products and services to be delivered include: Investigating the feasibility of aerosolizing and delivering...
This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...